{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:55:42Z","timestamp":1793307342364,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002992","name":"Department for International Development, UK Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002992","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malaria remains a major cause of morbidity and mortality in Africa, particularly in children under five years of age. Availability of effective anti-malarial drug treatment is a cornerstone for malaria control and eventual malaria elimination. Artemisinin-based combination therapy (ACT) is worldwide the first-line treatment for uncomplicated falciparum malaria, but the ACT drugs are starting to fail in Southeast Asia because of drug resistance. Resistance to artemisinins and their partner drugs could spread from Southeast Asia to Africa or emerge locally, jeopardizing the progress made in malaria control with the increasing deployment of ACT in Africa. The development of triple artemisinin-based combination therapy (TACT) could contribute to mitigating the risks of artemisinin and partner drug resistance on the African continent. However, there are pertinent ethical and practical issues that ought to be taken into consideration. In this paper, the most important ethical tensions, some implementation practicalities and preliminary thoughts on addressing them are discussed. The discussion draws upon data from randomized clinical studies using TACT combined with ethical principles, published literature and lessons learned from the introduction of artemisinin-based combinations in African markets.<\/jats:p>","DOI":"10.1186\/s12936-021-03649-7","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T11:02:53Z","timestamp":1614423773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations"],"prefix":"10.1186","volume":"20","author":[{"given":"Paulina","family":"Tindana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanaki","family":"Amaratunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Dhorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob W.","family":"van der Pluijm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen M.","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phaik Yeong","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"3649_CR1","unstructured":"WHO. World Malaria Report 2020. Geneva, World Health Organization, 2020. Accessed 10 February 2021."},{"key":"3649_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"3649_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"3649_CR4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s40265-018-0911-9","volume":"78","author":"EA Ashley","year":"2018","unstructured":"Ashley EA, Phyo AP. Drugs in development for malaria. Drugs. 2018;78:861\u201379.","journal-title":"Drugs"},{"key":"3649_CR5","doi-asserted-by":"crossref","unstructured":"Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, et al. New developments in anti-malarial target candidate and product profiles. Malar J. 2017;16:26.","DOI":"10.1186\/s12936-016-1675-x"},{"key":"3649_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12936-019-2724-z","volume":"18","author":"EG Tse","year":"2019","unstructured":"Tse EG, Korsik M, Todd MH. The past, present and future of anti-malarial medicines. Malar J. 2019;18:93.","journal-title":"Malar J"},{"key":"3649_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pt.2020.09.011","volume":"37","author":"RW van der Pluijm","year":"2021","unstructured":"van der Pluijm RW, Amaratunga C, Dhorda M, Dondorp AM. Triple artemisinin-based combination therapies for malaria - a new paradigm? Trends Parasitol. 2021;37:15\u201324.","journal-title":"Trends Parasitol"},{"key":"3649_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","volume":"395","author":"RW van der Pluijm","year":"2020","unstructured":"van der Pluijm RW, Tripura R, Hoglund RM, Pyae Phyo A, Lek D, Ul Islam A, et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020;395:1345\u201360.","journal-title":"Lancet"},{"key":"3649_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12936-019-2955-z","volume":"18","author":"NJ White","year":"2019","unstructured":"White NJ. Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance. Malar J. 2019;18:338.","journal-title":"Malar J"},{"key":"3649_CR10","doi-asserted-by":"crossref","unstructured":"Mairet-Khedim M, Leang R, Marmai C, Khim N, Kim S, Ke S, et al. Clinical and in vitro resistance of Plasmodium falciparum to artesunate-amodiaquine in Cambodia. Clin Infect Dis. 2020;ciaa628. Online ahead of print.","DOI":"10.1093\/cid\/ciaa628"},{"key":"3649_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1172\/JCI21682","volume":"113","author":"NJ White","year":"2004","unstructured":"White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113:1084\u201392.","journal-title":"J Clin Invest"},{"key":"3649_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/1475-2875-13-452","volume":"13","author":"Y Lubell","year":"2014","unstructured":"Lubell Y, Dondorp A, Guerin PJ, Drake T, Meek S, Ashley E, et al. Artemisinin resistance\u2013modelling the potential human and economic costs. Malar J. 2014;13:452.","journal-title":"Malar J"},{"key":"3649_CR13","unstructured":"United Nations Children\u2019s Fund. The convention on the rights of the child. https:\/\/www.unicef.org\/child-rights-convention. Accessed 6 July 2020."},{"issue":"Suppl 2","key":"3649_CR14","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1542\/peds.2014-1394H","volume":"134","author":"R Rhodes","year":"2014","unstructured":"Rhodes R, Holzman IR. Is the best interest standard good for pediatrics? Pediatrics. 2014;134(Suppl 2):S121\u20139.","journal-title":"Pediatrics"},{"key":"3649_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/15265161.2018.1485768","volume":"18","author":"LM Kopelman","year":"2018","unstructured":"Kopelman LM. Why the best interest standard is not self-defeating, too individualistic, unknowable, vague or subjective. Am J Bioeth. 2018;18:34\u20136.","journal-title":"Am J Bioeth"},{"key":"3649_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/dmcn.13608","volume":"60","author":"B Dan","year":"2018","unstructured":"Dan B. The child\u2019s best interest: ethical guide or ideology? Dev Med Child Neurol. 2018;60:4.","journal-title":"Dev Med Child Neurol"},{"key":"3649_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/inthealth\/ihw027","volume":"8","author":"PY Cheah","year":"2016","unstructured":"Cheah PY, White NJ. Antimalarial mass drug administration: ethical considerations. Int Health. 2016;8:235\u20138.","journal-title":"Int Health"},{"key":"3649_CR18","unstructured":"US Department of Health and Human Services (US DHHS). Federal policy for the protection of human subjects ('Common Rule'). 1991. Regulation 45 CFR part 46 FR 56\u2013117."},{"key":"3649_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1472-6939-15-12","volume":"15","author":"K Maung Lwin","year":"2014","unstructured":"Maung Lwin K, Cheah PY, Cheah PK, White NJ, Day NP, Nosten F, et al. Motivations and perceptions of community advisory boards in the ethics of medical research: the case of the Thai-Myanmar border. BMC Med Ethics. 2014;15:12.","journal-title":"BMC Med Ethics"},{"key":"3649_CR20","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1016\/S0140-6736(16)32519-3","volume":"388","author":"R Lim","year":"2016","unstructured":"Lim R, Peto TJ, Tripura R, Cheah PY. Village drama against malaria. Lancet. 2016;388:2990.","journal-title":"Lancet"},{"key":"3649_CR21","doi-asserted-by":"crossref","unstructured":"Lim R, Tripura R, T JP, Sareth M, Sanann N, Davoeung C, et al. Drama as a community engagement strategy for malaria in rural Cambodia. Wellcome Open Res. 2017;2:95.","DOI":"10.12688\/wellcomeopenres.12594.1"},{"key":"3649_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/11287462.2017.1411762","volume":"29","author":"C Nguon","year":"2018","unstructured":"Nguon C, Dysoley L, Davoeung C, Sovann Y, Sanann N, Sareth M, et al. Art and theatre for health in rural Cambodia. Glob Bioeth. 2018;29:16\u201321.","journal-title":"Glob Bioeth"},{"key":"3649_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12936-019-2976-7","volume":"18","author":"S Krishna","year":"2019","unstructured":"Krishna S. Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance: the case against. Malar J. 2019;18:339.","journal-title":"Malar J"},{"key":"3649_CR24","doi-asserted-by":"publisher","first-page":"a025619","DOI":"10.1101\/cshperspect.a025619","volume":"7","author":"D Menard","year":"2017","unstructured":"Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7:a025619.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3649_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1475-2875-6-72","volume":"6","author":"AA Amin","year":"2007","unstructured":"Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, et al. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J. 2007;6:72.","journal-title":"Malar J"},{"key":"3649_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/heapol\/czh051","volume":"19","author":"HA Williams","year":"2004","unstructured":"Williams HA, Durrheim D, Shretta R. The process of changing national malaria treatment policy: lessons from country-level studies. Health Policy Plan. 2004;19:356\u201370.","journal-title":"Health Policy Plan"},{"key":"3649_CR27","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"3649_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-3156.2006.01590.x","volume":"11","author":"JA Mulligan","year":"2006","unstructured":"Mulligan JA, Mandike R, Palmer N, Williams H, Abdulla S, Bloland P, et al. The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania. Trop Med Int Health. 2006;11:452\u201361.","journal-title":"Trop Med Int Health"},{"key":"3649_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12936-017-2102-7","volume":"16","author":"Group AC, Ujuju C, Anyanti J, Newton PN, Ntadom G","year":"2017","unstructured":"Group AC, Ujuju C, Anyanti J, Newton PN, Ntadom G. When it just won\u2019t go away: oral artemisinin monotherapy in Nigeria, threatening lives, threatening progress. Malar J. 2017;16:489.","journal-title":"Malar J"},{"key":"3649_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/1475-2875-10-326","volume":"10","author":"KA O'Connell","year":"2011","unstructured":"O\u2019Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, et al. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J. 2011;10:326.","journal-title":"Malar J"},{"key":"3649_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/1475-2875-10-327","volume":"10","author":"M Littrell","year":"2011","unstructured":"Littrell M, Gatakaa H, Evance I, Poyer S, Njogu J, Solomon T, et al. Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries. Malar J. 2011;10:327.","journal-title":"Malar J"},{"issue":"6 Suppl","key":"3649_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4269\/ajtmh.2007.77.193","volume":"77","author":"A Bosman","year":"2007","unstructured":"Bosman A, Mendis KN. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg. 2007;77(6 Suppl):193\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"3649_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4161\/23288604.2014.968005","volume":"1","author":"P Yadav","year":"2015","unstructured":"Yadav P. Health product supply chains in developing countries: diagnosis of the root causes of underperformance and an agenda for reform. Health Syst Reform. 2015;1:142\u201354.","journal-title":"Health Syst Reform"},{"key":"3649_CR34","doi-asserted-by":"publisher","unstructured":"Institute of Medicine. Saving lives, buying time: economics of malaria drugs in an age of resistance. Arrow KJ, Panosian C, Gelband H, Eds. Washington, DC: The National Academies Press. https:\/\/doi.org\/10.17226\/110172004.","DOI":"10.17226\/11017"},{"key":"3649_CR35","doi-asserted-by":"publisher","first-page":"e151228","DOI":"10.3201\/eid2203.151228","volume":"22","author":"T Sullivan","year":"2016","unstructured":"Sullivan T, Ben AY. Global introduction of new multidrug-resistant tuberculosis drugs-balancing regulation with urgent patient needs. Emerg Infect Dis. 2016;22:e151228.","journal-title":"Emerg Infect Dis"},{"key":"3649_CR36","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1473-3099(12)70064-6","volume":"12","author":"GM Nayyar","year":"2012","unstructured":"Nayyar GM, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis. 2012;12:488\u201396.","journal-title":"Lancet Infect Dis"},{"key":"3649_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/1475-2875-10-352","volume":"10","author":"PN Newton","year":"2011","unstructured":"Newton PN, Green MD, Mildenhall DC, Plancon A, Nettey H, Nyadong L, et al. Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. Malar J. 2011;10:352.","journal-title":"Malar J"},{"key":"3649_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12936-016-1200-2","volume":"15","author":"Group AC, Novotny J, Singh A, Dysoley L, Sovannaroth S, Rekol H","year":"2016","unstructured":"Group AC, Novotny J, Singh A, Dysoley L, Sovannaroth S, Rekol H. Evidence of successful malaria case management policy implementation in Cambodia: results from national ACTwatch outlet surveys. Malar J. 2016;15:194.","journal-title":"Malar J"},{"key":"3649_CR39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12936-017-1800-5","volume":"16","author":"Group AC, Phok S, Phanalasy S, Thein ST, Likhitsup A","year":"2017","unstructured":"Group AC, Phok S, Phanalasy S, Thein ST, Likhitsup A. Private sector opportunities and threats to achieving malaria elimination in the Greater Mekong Subregion: results from malaria outlet surveys in Cambodia, the Lao PDR, Myanmar, and Thailand. Malar J. 2017;16:180.","journal-title":"Malar J"},{"key":"3649_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.15171\/ijhpm.2016.30","volume":"5","author":"K Sheikh","year":"2016","unstructured":"Sheikh K, Uplekar M. What can we learn about the processes of regulation of tuberculosis medicines from the experiences of health policy and system actors in India, Tanzania, and Zambia? Int J Health Policy Manag. 2016;5:403\u201315.","journal-title":"Int J Health Policy Manag"},{"key":"3649_CR41","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/bmj.331.7519.734","volume":"331","author":"D Zurovac","year":"2005","unstructured":"Zurovac D, Ndhlovu M, Rowe AK, Hamer DH, Thea DM, Snow RW. Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study. BMJ. 2005;331:734.","journal-title":"BMJ"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03649-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-021-03649-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03649-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T11:06:24Z","timestamp":1614423984000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03649-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3649"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03649-7","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors are investigators in the DeTACT project with AD as the PI and PYC and PT leading the ethics component of the project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}